RH210A hearing aid performance in adults with mild-to-moderate hearing loss
Official title: Clinical Evaluation of the RH210 Hearing Aid Software Used With RH210A Device in Adults With Perceived Mild-to-Moderate Hearing Loss
Run by Rehear Audiology Company LTD · NCT07572357 · Data updated 2026-11-12
This study tests whether the RH210A hearing aid improves understanding of speech in noisy settings for adults with mild-to-moderate sensorineural hearing loss.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 24 (estimated) |
| Sponsor | Rehear Audiology Company LTD Industry-sponsored |
| Locations | 1 site (Macquarie Park, New South Wales) |
| Status | Recruiting |
| Started | April 11, 2026 |
| Main results expected | July 30, 2026 |
| Study ends | August 30, 2026 |
| Registry record updated | May 29, 2026 |
| Trial ID | NCT07572357 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 and older with self-perceived mild-to-moderate hearing loss who can use a smartphone and complete self-fitting via an app.
✕Probably not a fit
Individuals with conductive or mixed hearing loss, active ear pathology, or profound loss may not benefit from this device.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional investigation evaluates the RH210A air-conduction hearing aid in adults who perceive mild-to-moderate hearing difficulty. The primary goal is to show a clinically meaningful improvement in speech understanding in noise when using RH210A versus unaided listening, measured with the BKB-SIN test. Participants will use the device alongside Apple AirPods Pro (2nd Gen) with Hearing Aid Features and complete two in-person visits. The key endpoint is the mean 2 dB or greater improvement in SNR with RH210A compared to unaided listening. Safety and device performance will be monitored throughout the study.
Why it matters
Potential benefit: If successful, users could achieve better speech understanding in noisy environments with the RH210A device.
How similar studies have gone: Previous research in similar OTC-style hearing aid approaches has shown variable but encouraging improvements in speech-in-noise performance.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years * Self-perceived mild-to-moderate hearing difficulties/ hearing loss * Competent smartphone use (able to complete self-fitting via the app) * Able and willing to provide informed consent * HHIA screening consistent with perceived hearing difficulty * Willingness and ability to attend two in-person research appointments * Ability to operate a SmartPhone Exclusion Criteria: * Conductive or mixed hearing loss * Occluding cerumen * Otologic disease/ active ear pathology * Severe or profound hearing loss (PTA \>S0dBHL) (WHO, 2021) * Presence of (red-flag) conditions relevant to OTC hearing aid use (per 21 CFR 801.421) * Visible deformity of the ear (congenital or traumatic). * Fluid, pus, or blood coming from the ear (e.g., active drainage). * Sudden or rapidly progressive hearing loss within the recent past (often defined as within \~90 days). * Any acute or chronic dizziness or vertigo associated with hearing issues. * Pain or discomfort in or around the ear. * Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal. * Unilateral hearing loss of sudden onset or large asymmetry between ears. * Audiometric air-bone gap suggestive of possible conductive pathology (e.g., gap equal or more than 15 dB at key frequencies) * Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal. * Unilateral hearing loss of sudden onset or large asymmetry between ears
Where it's running
-
National Acoustic Laboratories
Macquarie Park, New South Wales, Australia Recruiting
Study contacts
- Principal investigator: Bettina Turnbull, Doctor of Audiology — National Acoustic Laboratories
- Study coordinator: Marisa Poulos, Master of Audiology
- Email: marisa.poulos@nal.gov.au
- Phone: +61 2 9412 6872
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Clemastine plus engineered sound to improve hearing in noisy environments for age-related central auditory processing disorder
This trial will test whether taking clemastine while listening to engineered sounds helps people aged 45–65 with age-related central auditory processing disorder hear better in noisy places.
-
How hearing aids affect understanding speech in noisy places
This project will test whether different hearing-aid directional settings help older adults with sensorineural hearing loss understand speech in noisy environments and whether simple spatial hearing measures predict who benefits.
-
Biomarkers in Congenital Hearing Loss: Alpha-Tectorin, IL-10, and Thiol-Disulfide Balance in Children
This observational study tests whether levels of alpha-tectorin, IL-10, and thiol-disulfide balance differ in children with congenital sensorineural hearing loss (with cochlear implants or hearing aids) compared with healthy children.
-
Anatomy-based fitting for single-sided deaf CI users
This study tests whether anatomy-based fitting changes how well adults with single-sided deafness use a cochlear implant to understand speech in noise and to enjoy music.
-
Long-term outcomes of MED-EL SONATA 2 Cochlear Implants in real life
This study looks at long-term results from people who received a SONATA 2 cochlear implant to see how well it works in everyday life.
-
Anatomy-Based Fitting for People with a Cochlear Implant and Hearing Aid
This study tests whether an anatomy-based frequency distribution works better than the default one for adults with a cochlear implant and a contralateral hearing aid.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.